The aim of the project was to reduce the prescribing of Gabapentin and Pregabalin.
The need for this project was initially highlighted by GP practice staff feeding back to prescribing leads that patients were increasingly requesting prescriptions for gabapentinoids before they were due for issue. This led to concerns about the potential overuse and dependency on gabapentinoids. In the UK, gabapentin is frequently prescribed in deprived areas, where there is a higher prevalence of chronic pain and other complex health issues. Following the concerns raised the guidance from the National Institute for Health and Care Excellence (NICE);
Neuropathic pain in adults: pharmacological management in non-specialist settings was reviewed. As NICE no longer recommends gabapentinoids for managing conditions like sciatica, low back pain, and chronic primary pain it was decided that efforts should therefore be made to review and potentially reduce these prescriptions due to the concerns about their long-term effects and risk/benefit profile.
The initiative was run by the multidisciplinary pharmacy team at the practice including, GPs, pharmacists, technicians, and clerks. Each patient underwent an individualised review and reduction plan, initiated by a GP and managed by a pharmacy technician.
The plan created per patient included a gradual reduction in the dose people received with the goal being to stop the medications completely.
Next steps included;
A spreadsheet-based system was established to track the active patients in the current project. The status was recorded as completed, in progress, or on hold. A waiting list was also established to fill spaces when active patients completed the reduction programme.
Medications were not on repeat with only the pharmacy team issuing supplies. A pop-up alert was created with all interventions coded on the patients records so all health care professionals were aware of the reduction programme including when reduction was completed.
Please login to view this content
Please login to view this content
Please login to view this content
Please login to view this content
Please login to view this content
Please login to view this content
Please login to view this content